Search

Your search keyword '"Girard, Philippe"' showing total 1,593 results

Search Constraints

Start Over You searched for: Author "Girard, Philippe" Remove constraint Author: "Girard, Philippe"
1,593 results on '"Girard, Philippe"'

Search Results

56. A Secret Among the Blacks: Slave Resistance Before the Haitian Revolution, by John D. Garrigus.

57. Uncloaking a cryptic, threatened rail with molecular markers: origins, connectivity and demography of a recently-discovered population

58. Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: post-hoc analysis of the PEP trial

59. Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients

60. Accuracy and interrater agreement of death event adjudications by physician trainees: validation of the ISTH definition of pulmonary embolism-related death in an autopsy cohort

61. Understanding PLM System Concepts to Facilitate Its Implementation in SME: The Real Case Study of POULT

62. Pulmonary embolism rule-out criteria (PERC) rule in European patients with low implicit clinical probability (PERCEPIC): a multicentre, prospective, observational study

66. Digestive Organ Aging and Cancer

67. Artificial intelligence and real-world data for drug and food safety – A regulatory science perspective

68. Artificial intelligence and real-world data for drug and food safety - A regulatory science perspective

70. Supplementary Table 1 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

71. Supplementary Methods and Figure Legend from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

72. Supplementary Figure 1 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

73. Supplementary Table 3 from Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC

74. Supplementary Figure 2 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

75. Supplementary Methods from Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC

76. Supplementary Table 2 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

77. Supplementary Table 2 from Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC

78. Supplementary Table 3 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

79. Supplementary Figure 1 from Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC

80. Supplementary Figure 3 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

81. Supplementary Table 4 from A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma

82. Supplementary Table 1 from Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC

83. Data from Cisplatin Resistance Associated with PARP Hyperactivation

84. Supplementary Table 1, Figures 1 - 8 from Cisplatin Resistance Associated with PARP Hyperactivation

100. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study

Catalog

Books, media, physical & digital resources